GSK plc (GSK) on Friday said China's National Medical Products Administration (NMPA) has approved Trelegy Ellipta for a new indication, allowing its use in adults aged 18 years and older with asthma. The approval expands the drug's existing authorization in China for the treatment of chronic obstructive pulmonary disease (COPD).
With the decision, Trelegy Ellipta—a combination of three active ingredients, fluticasone furoate, umeclidinium and vilanterol (FF/UMEC/VI)—becomes the first and only single-inhaler triple therapy approved in China for the long-term treatment of both asthma and COPD.
The approval was supported by results from GSK's CAPTAIN study, which showed that in patients whose asthma was not adequately controlled on inhaled corticosteroids combined with long-acting beta agonists (ICS/LABA), treatment with FF/UMEC/VI led to significantly greater improvements in lung function compared with FF/VI.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.